BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology, Inc. (TSX VENTURE:IXS) (OTCBB:IXSBF), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, today announced that Dr. J. Donald Capra, President Emeritus of the Oklahoma Medical Research Foundation (OMRF), has been appointed Chairman to InNexus’ newly formed Scientific Advisory Board.
